A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 Study

BACKGROUND: SAKURA 3 was a Phase 3, open-label, repeat-dose safety study of DaxibotulinumtoxinA for Injection (DAXI); a component of the largest Phase 3 clinical development program of an aesthetic neuromodulator in glabellar lines. OBJECTIVE: To evaluate the use of DAXI (40U) up to 3 treatments for...

Descripción completa

Detalles Bibliográficos
Autores principales: Green, Jeremy B., Mariwalla, Kavita, Coleman, Kyle, Ablon, Glynis, Weinkle, Susan H., Gallagher, Conor J., Vitarella, Domenico, Rubio, Roman G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752221/
https://www.ncbi.nlm.nih.gov/pubmed/32773447
http://dx.doi.org/10.1097/DSS.0000000000002463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752221/
https://www.ncbi.nlm.nih.gov/pubmed/32773447
http://dx.doi.org/10.1097/DSS.0000000000002463

Ejemplares similares